Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CNL and aCML should be considered as a single entity based on molecular profiles and outcomes.
Carreño-Tarragona G, Álvarez-Larrán A, Harrison C, Martínez-Ávila JC, Hernández-Boluda JC, Ferrer-Marín F, Radia DH, Mora E, Francis S, González-Martínez T, Goddard K, Pérez-Encinas M, Narayanan S, Raya JM, Singh V, Gutiérrez X, Toth P, Amat-Martínez P, Mcilwaine L, Alobaidi M, Mayani K, McGregor A, Stuckey R, Psaila B, Segura A, Alvares C, Davidson K, Osorio S, Cutting R, Sweeney CP, Rufián L, Moreno L, Cuenca I, Smith J, Morales ML, Gil-Manso R, Koutsavlis I, Wang L, Mead AJ, Rozman M, Martínez-López J, Ayala R, Cross NCP. Carreño-Tarragona G, et al. Among authors: morales ml. Blood Adv. 2023 May 9;7(9):1672-1681. doi: 10.1182/bloodadvances.2022008204. Blood Adv. 2023. PMID: 36375042 Free PMC article.
NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy.
Hurtado-Navarro L, Cuenca-Zamora EJ, Zamora L, Bellosillo B, Such E, Soler-Espejo E, Martínez-Banaclocha H, Hernández-Rivas JM, Marco-Ayala J, Martínez-Alarcón L, Linares-Latorre L, García-Ávila S, Amat-Martínez P, González T, Arnan M, Pomares-Marín H, Carreño-Tarragona G, Chen-Liang TH, Herranz MT, García-Palenciano C, Morales ML, Jerez A, Lozano ML, Teruel-Montoya R, Pelegrín P, Ferrer-Marín F. Hurtado-Navarro L, et al. Among authors: morales ml. Cell Rep Med. 2023 Dec 19;4(12):101329. doi: 10.1016/j.xcrm.2023.101329. Cell Rep Med. 2023. PMID: 38118408 Free PMC article.
Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma.
Ortiz-Ruiz A, Ruiz-Heredia Y, Morales ML, Aguilar-Garrido P, García-Ortiz A, Valeri A, Bárcena C, García-Martin RM, Garrido V, Moreno L, Gimenez A, Navarro-Aguadero MÁ, Velasco-Estevez M, Lospitao E, Cedena MT, Barrio S, Martínez-López J, Linares M, Gallardo M. Ortiz-Ruiz A, et al. Among authors: morales ml. Cancers (Basel). 2021 Apr 1;13(7):1662. doi: 10.3390/cancers13071662. Cancers (Basel). 2021. PMID: 33916196 Free PMC article.
High-Throughput CRISPR Screening in Hematological Neoplasms.
Ancos-Pintado R, Bragado-García I, Morales ML, García-Vicente R, Arroyo-Barea A, Rodríguez-García A, Martínez-López J, Linares M, Hernández-Sánchez M. Ancos-Pintado R, et al. Among authors: morales ml. Cancers (Basel). 2022 Jul 25;14(15):3612. doi: 10.3390/cancers14153612. Cancers (Basel). 2022. PMID: 35892871 Free PMC article. Review.
Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms.
Cortés AA, Diaz RA, Hernández-Campo P, Gorrochategui J, Primo D, Robles A, Morales ML, Ballesteros J, Rapado I, Gallardo M, Linares M, Martínez-López J. Cortés AA, et al. Among authors: morales ml. Haematologica. 2019 May;104(5):937-946. doi: 10.3324/haematol.2018.201038. Epub 2018 Dec 13. Haematologica. 2019. PMID: 30545926 Free PMC article.
Long-Term Human Hematopoietic Stem Cell Culture in Microdroplets.
Carreras P, González I, Gallardo M, Ortiz-Ruiz A, Morales ML, Encinas J, Martínez-López J. Carreras P, et al. Among authors: morales ml. Micromachines (Basel). 2021 Jan 16;12(1):90. doi: 10.3390/mi12010090. Micromachines (Basel). 2021. PMID: 33467039 Free PMC article.
Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy.
Rodríguez-García A, Morales ML, Garrido-García V, García-Baquero I, Leivas A, Carreño-Tarragona G, Sánchez R, Arenas A, Cedena T, Ayala RM, Bautista JM, Martínez-López J, Linares M. Rodríguez-García A, et al. Among authors: morales ml. Antioxidants (Basel). 2019 Oct 24;8(11):508. doi: 10.3390/antiox8110508. Antioxidants (Basel). 2019. PMID: 31652983 Free PMC article.
109 results